Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Jiangsu Hengrui Pharmaceuticals Co PB Ratio?
Jiangsu Hengrui Pharmaceuticals CoJHPCY 71 PB Ratio is 4.89 as of Jul. 30, 2026, which is 47% below its 10-year median of 9.27. GuruFocus rates JHPCY with a GF Score™ of 71/100 and a GF Value™ of $15.12 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 921 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks worse than 86.1% on this metric.
JHPCY'
s PB Ratio Range Over the Past 10 Years
Min: 4.91 Med: 9.27 Max: 21.71
Current: 5.7
During the past 13 years, Jiangsu Hengrui Pharmaceuticals Co's highest PB Ratio was 21.71. The lowest was 4.91. And the median was 9.27.
JHPCY's PB Ratio is ranked worse than 86.1% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.86
vs JHPCY: 5.70
During the past 12 months, Jiangsu Hengrui Pharmaceuticals Co's average Book Value Per Share Growth Rate was 34.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 15.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 18.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Jiangsu Hengrui Pharmaceuticals Co was 91.90% per year. The lowest was 2.20% per year. And the median was 24.95% per year.
Back to Basics: PB Ratio
Jiangsu Hengrui Pharmaceuticals Co (OTCPK:JHPCY) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Jiangsu Hengrui Pharmaceuticals Co PB Ratio Related Terms
Jiangsu Hengrui Pharmaceuticals Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's PB Ratio falls into.
Jiangsu Hengrui Pharmaceuticals Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Jiangsu Hengrui Pharmaceuticals Co (JHPCY) has a PB Ratio of 4.89 as of Jul. 30, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 47% below median its historical median of 9.27. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's PB Ratio has ranged from 4.91 to 21.71. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #793 out of 921 companies in the Drug Manufacturers industry, placing it in the top 86.1%.
Is Jiangsu Hengrui Pharmaceuticals Co's PB Ratio too high?
Jiangsu Hengrui Pharmaceuticals Co's current PB Ratio of 4.89 is 47% below median its 10-year median of 9.27. Over the past 10 years, this metric has ranged from a low of 4.91 to a high of 21.71. The Drug Manufacturers industry median PB Ratio is 1.86. Jiangsu Hengrui Pharmaceuticals Co's value of 4.89 is 162.9% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #793 out of 921 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #793 out of 921 companies for PB Ratio. This places Jiangsu Hengrui Pharmaceuticals Co in the lower half of its industry. The industry median PB Ratio is 1.86. Jiangsu Hengrui Pharmaceuticals Co's value of 4.89 is 162.9% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own PB Ratio has ranged from 4.91 to 21.71 over the past decade. While the company's 10-year median is 9.27 vs. the industry median of 1.86, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current PB Ratio of 4.89 is 162.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current PB Ratio is 4.89, which is 47% below median its own 10-year median of 9.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (JHPCY) is currently considered Modestly Undervalued. The stock's GF Value™ is $15.12, compared to a current price of $13.60 — trading 10.1% below its estimated fair value. The current PB Ratio is 4.89, which is 47% below median its 10-year median of 9.27 and 162.9% above the Drug Manufacturers industry median of 1.86. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (JHPCY), the current PB Ratio is 4.89 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (JHPCY) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of $13.60 is trading 10.1% below its estimated GF Value™ of $15.12.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for JHPCY:
PB Ratio: 4.89 (47% below median its 10-year median of 9.27)
GF Value™: $15.12 vs. price of $13.60 (10.1% below fair value)
Industry Position: 162.9% above the Drug Manufacturers median (#793 of 921)
No single metric tells the full story. See the JHPCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
71GF Score
Get the complete analysis for JHPCY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JHPCY has been successfully added to your 
